US 12,188,936 B2
Biomarkers and therapeutics for endocrine therapy resistance
Michael P. Lisanti, Manchester (GB); Federica Sotgia, Manchester (GB); and Marco Fiorillo, Manchester (GB)
Assigned to LUNELLA BIOTECH, INC., Ontario (CA)
Appl. No. 15/734,030
Filed by LUNELLA BIOTECH, INC., Ottawa (CA)
PCT Filed May 30, 2019, PCT No. PCT/US2019/034575
§ 371(c)(1), (2) Date Dec. 1, 2020,
PCT Pub. No. WO2019/232161, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/679,379, filed on Jun. 1, 2018.
Prior Publication US 2021/0215702 A1, Jul. 15, 2021
Int. Cl. G01N 33/574 (2006.01); A61K 31/138 (2006.01); A61K 31/404 (2006.01); A61K 31/454 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/519 (2006.01); A61K 31/538 (2006.01); A61K 31/65 (2006.01)
CPC G01N 33/57488 (2013.01) [A61K 31/138 (2013.01); A61K 31/404 (2013.01); A61K 31/454 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/519 (2013.01); A61K 31/538 (2013.01); A61K 31/65 (2013.01)] 35 Claims
 
1. A method for identifying and treating endocrine therapy resistance due to the Y537S mutation of estrogen receptor ESR1 in a breast cancer, the method comprising:
obtaining a biological epithelial sample of the cancer from a patient;
determining, or having determined, the level of a plurality of biomarkers prognostic of endocrine therapy resistance in the biological epithelial sample selected from HSPD1, GRPEL1, MRPL15, MRPS16, COX4|1, ENO1, ENO2, MRPL4, AKAP1, PTRH2, HSPA9, and TALDO1;
comparing the determined level to a threshold level from MCF7 cells transduced with ESR1 (wild type) for the plurality of biomarkers; and
administering to the patient a pharmaceutically effective amount of a combination of an oxidative metabolism inhibitor and a glycolytic metabolism inhibitor if the determined level exceeds the threshold level.